In the current study, a novel coreceptor-specific cell-cell fusion (CCF) assay system is reported. The system possesses the following features: dual CCR5-dependent and CXCR4-dependent CCF assays, all stable cell lines, inducible expression of gp160 to minimize cytotoxicity, robust luciferase reporter, and 384-well format. These assays have been validated using various known HIV entry inhibitors targeting various stages of the HIV entry/fusion process, including fusion inhibitors, gp120 inhibitors, CCR5 antagonists, CCR5 antibodies, and CXCR4 antagonists. IC 50 data generated from this assay system were well correlated to that from the antiviral assays. The effects of DMSO on this assay system were assessed, and a 2-to 3-fold increase in luciferase activity was observed in the presence of 0.05% to 2% DMSO. Although cell-cell fusion efficiency was enhanced, no changes in drug response kinetics for entry inhibitors were found in the presence of 0.1% or 0.5% DMSO. This assay system has been successfully used for the identification and characterization of thousands of CCR5 inhibitors. (Journal of Biomolecular Screening 2006:65-74) 
INTRODUCTION
H IV ENTERS HOST CELLS VIA a virus-cell fusion mechanism. [1] [2] [3] [4] Three important molecules are involved in this process: viral surface envelope protein gp160, host cell surface receptor CD4, and chemokine coreceptors. The tropism of the HIV virus is determined by gp120 on the HIV envelope and the chemokine receptor CCR5 or CXCR4 on the host cell membrane. 4 An HIV virus that uses CCR5 as a coreceptor is called a macrophage-tropic (Mtropic) virus or R5-virus; if the virus uses CXCR4 as a coreceptor, then it is called T lymphocyte-tropic (T-tropic) virus or X4-virus; if the virus can use both CCR5 and CXCR4 as a coreceptor, then it is a dual-tropic (R5/X4) virus. Most HIV virions in primary or early infections are R5-viruses. 5 There has been a growing interest in new anti-HIV agents to tackle the growing problems of multidrug resistance. Host and viral molecules involved in various stages of HIV entry have been explored as novel targets for the discovery of anti-HIV agents, [1] [2] [3] of which HIV coreceptor CCR5 has been particularly favored. 6 Many very potent CCR5 antagonists have been identified in recent years that have showed potent antiviral effects both in cell culture and in clinical trials. [6] [7] [8] In addition, many other small-molecule inhibitors or antibodies targeting other HIV attachment/entry sites have been in various stages of development. Therefore, there is a strong need for a universal robust assay system for the identification of various HIV entry inhibitors. Traditionally, most CCR5 antagonists were identified by using I 125 -labeled ligand-binding assays. Recent studies revealed that the potency of CCR5 antagonists or antibodies in ligand-binding assays and antiviral assays is not well correlated (unpublished data). 8 Although it is impractical to use antiviral assays for large-scale routine screen or structure-activity relationship (SAR) studies for HIV entry inhibitors, a high-throughput compatible cell-based surrogate functional assay system will be highly desired for this purpose.
A variety of cell-based surrogate assay systems have been reported that mimic the HIV virus-cell fusion. [9] [10] [11] [12] [13] [14] [15] [16] Broadly speaking, these assays fall into the following 2 categories: pseudotyped HIVcell fusion 15, 16 and cell-cell fusion (CCF). [9] [10] [11] [12] [13] [14] In the pseudotyped HIV-cell fusion assay, an attenuated HIV virus or other viral particles that carry HIV envelope proteins were used as fusion vehicles. Limitations of pseudotyped assays are the need for preparing fresh viral particles and lengthy incubation time. These assays are not suitable for testing large quantities of entry inhibitors.
CCF assay is based on the observation that HIV-infected human cells can fuse to uninfected cells via a mechanism similar to HIV virion-cell fusion. A number of different CCF assay systems have been reported that use various cell lines and fusion detection approaches. [9] [10] [11] [12] [13] [14] However, few of these assay systems were suitable for a high-throughput format. 9, 10 Besides, all of the published highthroughput compatible CCF assays are based on R5 gp160 only; hence, they cannot be used for the detection of CXCR4 antagonists. In this article, a novel dual high-throughput compatible CCF assay system is described. It is composed of 2 very similar assays: the CCR5-dependent (R5-CCF) and CXCR4-dependent CCF (X4-CCF) assays. Because the effector cells for both R5-CCF and X4-CCF assays were from the same parental cell line and the target cells in both assays were from similar T lymphoma cells, this makes the assay system especially useful in screening CCR5 or CXCR4 antagonists. In these cases, the 2 assays could be used as a cross-counterscreen for each other to eliminate nonspecific or cytotoxic hitters. In addition, evidence shows that R5 and X4 viruses respond differently to some coreceptor-independent entry inhibitors, and this assay system would be ideal for obtaining such information.
Due to cytotoxicity of HIV gp120 to many cell types, [17] [18] [19] transient transfection or infection with a virus vector was used in most of the published assays to express gp160 in the effector cells. 9, [12] [13] [14] In the current report, an inducible expression system was successfully introduced into the effector cells to control the expression of gp160 for the 1st time. Because both effector and target cells used in the dual assay system were stable cell lines, the assays are highly robust and reproducible, thus highly suitable for high-throughput screening (HTS). This assay system has been validated by detecting inhibitors that target various steps of HIV entry.
MATERIALS AND METHODS

Reagents
Cell culture media and fetal bovine sera were purchased from Invitrogen (Carlsbad, CA). Human CCR5 monoclonal antibody 2D7, CXCR4 antibody 1D9, CD4 antibody, and PE-conjugated goat anti-mouse antibodies were purchased from Pharmingen (San Diego, CA). Anti-gp120 antibody was purchased from Fitzgerald Industries International (Concord, MA). CXCR4 antagonist T-22 was purchased from BACHEM Bioscience (Philadelphia, PA). HIV fusion/entry inhibitors AMD3100 (CXCR4 antagonist); SCH-C, SCH-D, UK427,857, and GW873140 (CCR5 antagonist); BMS-806 (CD4-gp160 inhibitor); and all other CCR5 small-molecule antagonists tested in cell-cell fusion assays for SAR studies were synthesized at Roche (Palo Alto, CA).
Expression plasmids construction
The complete coding sequence of HIV-1 NL-43 (GenBank Accession No. M19921) Tat was amplified from a NL-43 provirus plasmid clone by PCR using the following primers: 5′-ATGGAGCCAGTAGATCCTAGACTAG-3′ and 5′CTATTCCTTCGGGCCTGTCGGGTCCCCTCGGGATTGGG AGGTGGGTTGCTT-TGATAGAGAAGC-3′. The PCR product (contains both exon 1 and exon2) was cloned into pTarget vector (Promega, Madison, WI) by TA cloning, and the resulting clone pTarget-Tat was used as a template to amplify the Tat coding sequence using a different set of primers: 5′-GCGGGAATTCGCCACCATGGAGCCAGTAGATCCTAGAC -3′ and 5′-GCGGGGATCCTTTTCCTTCGGGCCTGTCGG-3′. The PCR product was digested with EcoR I and BamH I and ligated to predigested expression vector pZsGreen-N1 (BD Biosciences Clontech, Palo Alto, CA) to generate construct pZSG-Tat for the expression of Tat-green fluorescent protein (GFP) fusion protein. The envelope coding sequences, including the rev genes of CXCR4-tropic HIV virus NL-43 and CCR5-tropic HIV virus 92US715 (GenBank Accession No. U08451, obtained from the National Institutes of Health [NIH] AIDS Research & Reference Reagents Program), were amplified using primers 5′-GGTTGCTTTCATTGCCAAGTTT-GTTTC-3′ and 5′-CGCACGCGTACTACTTTTTGACCACTTGCCACCCAT-3′, and the amplified DNA were cloned into pcDNA3.1/V5-His-TOPO vector (Invitrogen, Carlsbad, CA). The inserts were then recloned into the pTRE2hyg vector (BD Biosciences Clontech, Palo Alto, CA) by restriction digestions with EcoR I and Xho I, and the resulting constructs were called pTRE2-R5-env and pTRE2-X4-env, respectively.
Generation of stable effector cell lines expressing HIV gp160 and Tat proteins
To establish stable cell lines expressing HIV envelope protein gp160 and Tat proteins, HeLa-tet-on cells (BD Biosciences, Palo Alto, CA) were cotransfected with pZSG-Tat and pTRE2-R5-env or pTRE2-X4-env using 50 µL of Fugen 6 (Roche Applied Sciences, Indianapolis, IN) mixed with 5 µg of each plasmid per 100mm culture dish. The transfected cells were split into six 100-mm culture dishes and selected in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 1 × Pen-Strep, 400 µg/mL G418, and 200 µg/mL hygromycin. GFPpositive cell colonies (expressing Tat protein) were expanded and screened for gp160 expression by monitoring cell-cell fusion activity in syncytia formation and cell-cell fusion assays as described below. The clones showing good fusion activities in both assay systems were further characterized in CCF assays in a 96-well format using fusion inhibitors for specificity and sensitivity. The R5virus gp160-expressing stable clone HeLa-R5 and X4-virus gp160-expressing stable clone HeLa-X4 with robust signal and low noise background were used in this study. The expression of the gp160 on these cells was confirmed by fluorescence-activated cell sorting (FACS) using gp120 antibodies.
Target cells and other cell lines
The target cell CEM-NKr-CCR5-Luc (CEM-R5) used in the CCR5-specific CCF assay is obtained from the NIH AIDS Research & Reference Reagents Program. This stable cell line expresses CD4 and CCR5 and carries an HIV-2 long terminal repeat (LTR)-driven luciferase reporter gene. This cell line is maintained in RPMI-1640 containing 10% FBS, 4 mM glutamine, and 800 µg/mL Geneticin (G418). The target cell CEMx174 5.25 M7 (5.25) cell line was obtained from Ned Landau (SALK Institute, La Jolla, CA). This cell line expresses CD4, CXCR4, and CCR5 and carries an LTR-luciferase and LTR-GFP cassette and was maintained in RPMI-10% FBS containing 1 × Pen-Strep (100 U penicillin and 100 µg streptomycin per mL), 200 µg/mL G418 (Invitrogen, Carlsbad, CA), 200 µg/mL hygromycin (Invitrogen, Carlsbad, CA), and 0.5 µg/mL puromycin (Sigma-Aldrich, St. Louis, MO). The 5.25 cell line showed a low expression of CCR5 when received and rapidly lost CCR5 expression completely. The MAGI-CCR5 (U373-MAGI-CCR5E) and MAGI-CXCR4 (U373-MAGI-CXCR4CEM) indicator cell lines were obtained from the NIH AIDS Research & Reference Reagents Program. Both MAGI-CCR5 and MAGI-CXCR4 cells were maintained in DMEM supplemented with 10% FBS, 4 mM glutamine, and 200 µg/mL G418, 1 × Pen-Strep, 100 µg/mL hygromycin B, and 1 µg/ mL puromycin. The expression of CD4, CCR5, and CXCR4 on the indicator cell lines was confirmed by FACS analyses using appropriate antibodies.
FACS analysis
The expression of gp120, CD4, CCR5, and CXCR4 on various cells used in this study was examined by FACS. Cells were harvested and washed twice in phosphate-buffered saline (PBS) containing 0.5% FBS (FACS buffer), then resuspended in FACS buffer at 4 × 10 6 cells/mL. For each reaction, 25 µL of cells (1 × 10 5 ) was transferred to a 5-mL tube, 1 µg of various primary antibodies and isotype controls was added, and the cells were incubated on ice for 30 to 45 min. Cells were washed 3 times in FACS buffer and incubated with PE-labeled anti-mouse secondary antibodies for 30 min on ice. At the end of incubation, cells were washed 3 times and resuspended in 300 µL of FACS buffer, and the stained cells were analyzed with a FACScan Calibur flow cytometer (Becton Dickinson, San Jose, CA).
Cell-cell fusion assays
HeLa-R5 or HeLa-X4 cells were plated in 384-well white culture plates (BD Bioscience, Palo Alto, CA) at 7.5 × 10 3 cells per well in phenol red-free DMEM supplemented with 10% FBS, 1x Pen-Strep, 300 µg/mL G418, 100 µg/mL hygromycin, and 1 µg/ mL Doxycycline (Dox) (BD Bioscience, Palo Alto, CA) using Multimek (Beckman, Fullerton, CA) and incubated at 37°C overnight to induce the expression of gp160. The target cells CEM-R5 or 5.25 in the phenol red-free growth medium were then added to the plates at 1.5 × 10 4 cells/15 µL/well and incubated for 20 to 24 h. At the end of coculture, 15 µL of Steady-Glo luciferase substrate was added into each well, and the cultures were sealed and gently shaken for 45 min. The luciferase activity was measured for 10 s per well as luminescence by using the 16-channel TopCount NXT (PerkinElmer, Shelton, CT) with 10-min dark adaptation, and the readout is counts per second (CPS). When small-molecule compounds or antibodies needed to be added to the CCF assay system, the compounds were either diluted manually or by using the robot Platemate 2 × 2 (Matrix, Hudson, NH) in serum-free and phenol red-free RPMI containing 5% DMSO (CalBiochem, La Jolla, CA) and 1 × Pen-Strep on 384-well V-bottom dilution plates (BD Bioscience, Palo Alto, CA). Then, 10 µL of the diluted compounds was added to the effector cells (HeLa-R5 or HeLa-X4) just before the addition of target cells, thus making the final concentration of DMSO in the coculture 0.5% (total volume 50 µL).
Syncytia formation assay using MAGI indicator cells
HeLa-R5 or HeLa-X4 cells were grown in DMEM containing 10% FBS, 1 × Pen-Strep, 400 µg/mL G418, 200 µg/mL hygromycin, and 1 µg/mL Dox to induce gp160 expression for 24 h. Cells were detached and plated at a 1:1 ratio with either MAGI-CCR5 or MAGI-CXCR4 cells in 48-well plates at 3 × 10 4 cells per well in RPMI medium supplemented with 10% FBS. After 6 h of coculture, the cells were stained for β-galactosidase (β-gal) activity using the β-Gal Staining kit (Invitrogen, Carlsbad, CA). Cells were rinsed once with phosphate-buffered saline (PBS), then fixed with PBS containing 2% formaldehyde and 0.2% glutaraldehyde for 10 min at room temperature. The cells were rinsed twice with PBS, stained in PBS containing 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM magnesium chloride, and 1 mg/mL X-gal at 37°C for 1 h or until sufficient blue staining developed. Syncytia were visualized under a light microscope.
Syncytia formation assay using CEM-R5 and 5.25 target cells
HeLa-R5-16 or HeLa-X4-6 cells were plated in 48-well plates at 3 × 10 4 cells per well in RPMI medium supplemented with 10% FBS and 1 µg/mL Dox to induce gp160 expression. After 24 h of incubation, 5 × 10 4 of CEM-R5 or 5.25 cells in RPMI medium containing 10% FBS were added to the wells. At 6 or 24 h of coculture, the cells were photographed under a microscope at 160× magnitude.
Antiviral assay
The antiviral assay was performed by infecting JC53-BL indicator cells with CCR5-tropic HIV NL-Bal virus (obtained from the NIH AIDS Research & Reagents Program) in the presence of CCR5 antagonists. JC53-BL are HeLa-derived cells that express a high level of CD4, CCR5, and CXCR4 and carry an LTR-driven luciferase and an LTR-driven β-gal reporter. Briefly, JC53-BL cells were plated in 96-well tissue culture plates at 5 × 10 3 cells/ well in DMEM containing 10% FBS. The following day, serially diluted CCR5 antagonists were added to the cells, followed by the addition of the NL-Bal virus. The infected cells were cultured at 37°C for 2 days, and then Steady-Glo luciferase substrate was Dual CCR5-and CXCR4-Dependent Cell-Cell Fusion Assay added and the luciferase activity measured. Percent inhibition of luciferase activity was calculated for each dose point after subtracting the background, and IC 50 was determined by using XLfit.
Statistical analysis of data
The difference between 2 populations was determined by using ANOVA (single-factor analysis tool), and a p-value of 0.05 or smaller was considered statistically significant. Linear regression analysis was performed by using Microsoft Excel, and coefficient r 2 values were generated to determine if a correlation existed between 2 data sets. Z′ factor values were calculated using the equation defined by Zhang et al 20 
. SD high and SD low are the corresponding standard deviations of the Mean high and Mean low values. High and low refer to the maximum and minimum signals produced by the CCF assay system.
RESULTS
CCF assay system design and development
A dual R5-CCF and X4-CCF assay system was designed, as depicted in Figure 1 . In both R5-CCF and X4-CCF assays, an effector and a target cell were used. The HeLa-tet-on cells were used to establish the stable effector cell lines that constitutively express HIV Tat (activator) and HIV gp160 only when induced by Dox. To minimize the cytotoxicity of gp160, these HeLa effector cells were maintained in growth medium without Dox to shut down gp160 expression and were induced to express gp160 24 h prior to the assays. When these induced effector cells were mixed with target cells, gp160 on the effector cell surface and CD4 and chemokine receptor on the target cells will mediate the cell-cell fusion process, and once the 2 types of cells are fused, Tat protein from the effector cells will activate the LTR promoter, which triggers the luciferase reporter gene expression. The specificity of these assays was determined by the cell-cell fusion between appropriate gp160 and coreceptor-expressing cells (Fig. 1) .
The assays were initially run in a 96-well format and later optimized for the 384-well format to improve throughput. Most experimental conditions were determined by using the R5-CCF assay system, and these conditions also proved to be ideal for the X4-CCF assay system (data not shown). A large range of cell numbers and ratios of both effector and target cells was tested in the 384well format. It was found that the highest reporter signal was achieved when effector-to-target cells were at ratios of 1:2 ( Fig.  2A) . In addition, the cell numbers for the HeLa-R5 and CEM-R5 cells that produced consistently the highest reporter activity were 7.5 × 10 3 and 1.5 × 10 4 cells per well, respectively (Fig. 2B) .
To evaluate whether the CCF assays are coreceptor specific, effector cells carrying gp160 either from an R5-virus (HeLa-R5) or an X4-virus (HeLa-X4) were incubated with target cells expressing either CCR5 (CEM-R5) or CXCR4 (5.25) , and the fusion between these cells was monitored by luciferase expression. As shown in Figure 2C , a robust luciferase reporter signal was generated either when HeLa-R5 cells were cocultured with CEM-R5 cells or when HeLa-X4 cells were cocultured with 5.25 cells. However, under the same assay conditions, no significant luciferase expression was detected either when HeLa-R5 cells were cocultured with 5.25 cells or HeLa-X4 cells were cocultured with 
Fused Cell
Tat drives the expression of luciferase reporter CEM-R5 cells. These data demonstrated that this CCF assay system is highly coreceptor dependent, and the non-coreceptormediated cell-cell fusion was undetectable.
Time course of the CCF assay
To determine the fusion assay kinetics, a time course study was performed. The luciferase signal was produced after 3 h of the coculture, and the signal rapidly increased until it reached a plateau from 12 to 48 h (Fig. 3) , providing a large time window. Based on these data, 20 to 24 h of coculture was used in all CCF assays. Minimal variation in assay parameters was noticed in this coculture time frame. The maximal luciferase signal variation for the R5-CCF assays was less than 5%.
Visualization of cell-cell fusion by syncytia formation
To confirm that the effector cells can fuse to the target cells or any cells that express CD4 and appropriate chemokine receptors, syncytia formation was monitored under a microscope. For better visualization of syncytia formed between gp160-expressing HeLa cells and coreceptor-expressing MAGI cells, the circularly tandem nuclei within the fused cells were positively stained for β-gal expression. When HeLa-R5 cells were mixed with MAGI-CCR5 or CEM-R5 cells, about 20% to 40% of the cells were fused. However, no syncytia were found when HeLa-R5 were cocultured with MAGI-CXCR4 or 5.25 cells. Similarly, significant cell-cell fusion was found in HeLa-X4 and MAGI-CXCR4 or 5.25 cocultures (~20%-40% of total cells) but not in HeLa-X4 and MAGI-CCR5 or CEM-R5 cocultures. Large numbers of fused cells were formed by 5 h of coculture (~20%), and they became even more significant by 24 h of coculture (~30%) (Fig. 4) . These data suggest that these effector cells can successfully fuse to the corresponding target cells, and the fusion is highly coreceptor dependent.
Effect of DMSO on CCF assays
Although this assay system can be used to determine the IC 50 s for protein inhibitors, most HIV entry inhibitors are smallmolecule compounds that are usually dissolved in DMSO. Introduction of DMSO into the CCF assay system is inevitable if small-molecule compounds are to be tested. Because DMSO is one of the organic chemicals that have been known to enhance membrane fusion, 21, 22 DMSO effects on cell-cell fusion and the tolerable dose range were examined. DMSO at concentrations from 0.05% to 5% was applied to the R5-CCF assay system, and a significant boost in membrane fusion was observed in the dose range of 0.01% to 2%. More than 2% of the DMSO began to exhibit a cytotoxic effect (Fig. 5A) . It is important to know whether the boosted fusogenicity between the 2 cell types will change the potency of the test compounds on the cell-cell fusion. To answer this question, 2 HIV entry inhibitors (SCH-C and ENF) were tested in the CCF assay system in the absence and presence of 0.1% or 0.5% DMSO. No differences in IC 50 s were found in the absence or presence of DMSO at either concentration, suggesting that the drug responses were not affected by the presence of DMSO at concentrations up to 0.5% (Fig. 5B) . This observation is consistent with published findings that enhanced fusion efficiency does not change cell-cell fusion kinetics. 23 These data thus support that our assay system could be used for large-scale screening of small-molecule inhibitors dissolved in DMSO. A final DMSO concentration of 0.5% was made standard for all CCF assays used in this study.
Evaluation of known HIV entry inhibitors in CCF assays
To further validate the specificity and accuracy of this CCF assay system, several known HIV entry inhibitors targeting various stages of the entry process were tested, and their determined IC 50 s were found to be consistent with published data ( Table 1) . Examples of the dose-response curves of these inhibitors in the CCF assays are shown in Figure 6 . HIV fusion inhibitor ENF and HIV gp120 inhibitor BMS-806 inhibited both CCR5-dependent and CXCR4-dependent CCF assays, whereas CCR5 antagonists SCH-C, SCH-D, GW873140, and UK427,857 only inhibited the CCR5specific CCF assay, and CXCR4 antagonists T-22 and AMD3100 only inhibited CXCR4-specific CCF assays. These results also demonstrate that this CCF assay system is highly coreceptor specific.
Use of CCF assays for CCR5 antagonist SAR studies
The CCR5-dependent CCF assay was successfully used for the SAR studies of CCR5 antagonists, in which the X4-CCF assay was used as a counterscreen to eliminate cytotoxic or non-CCR5specific compounds. Thousands of CCR5 antagonists have been tested in the CCF assay system, and the IC 50 values determined were highly reproducible. In addition, several important assay parameters were analyzed for this CCF assay system. The Z′ factors for the CCR5-and CXCR4-dependent CCF assays were determined as 0.67 and 0.66, respectively. A signal/noise (maximal signal/minimal signal) ratio of over 60 was observed for both CCR5-and CXCR4-CCF assays ( Table 2) . Because the CCF assay is a mimic of cell-cell fusion in vivo, similar drug response kinetics between the CCF assays and antiviral assays is anticipated. In fact, there is vast amount of evidence showing that IC 50 s generated from the CCF assays are closely related to those generated from antiviral assays. [9] [10] [11] [12] [13] [14] [15] [16] In the current study, some of the CCR5 antagonists tested in CCF assays were also tested in antiviral assays. A total of 207 CCR5 antagonists with IC 50 s ranging from 0.4 nM to 50 µM in these assays were analyzed, and a good correlation was found between the 2 IC 50 value groups (r 2 = 0.834) ( Fig. 7) . Although only about 20 CCR5 inhibitors that showed IC 50 s greater than 1 µM were also tested in antiviral assays, the IC 50 values for these weak inhibitors determined from both assays were also highly correlated, indicating that the R5-CCF assay is highly sensitive. These data suggest that the CCF assay system can be used to detect CCR5 inhibitors of a wide range of antiviral activities with good accuracy. These data, together with the IC 50 data for various known HIV entry inhibitors, further validated this assay system as a powerful surrogate assay for identifying and characterizing HIV entry inhibitors. 
DISCUSSION
To achieve high fusion efficiency between the 2 cell types, a moderate to high level of gp160 expression in effector cells is necessary. Published literature suggests that stable expression of gp160 in some cell types leads to cell toxicity, variation in expression, and eventual decline in expression. [17] [18] [19] Therefore, in most of the cell-cell fusion assays reported, gp160 was transiently expressed in effector cells via transient transfection or virusmediated expression. 9, [12] [13] [14] However, these transient expression approaches add extra steps and variability to the assays and thus are less suitable for high throughput. To overcome potential gp160 cytotoxicity associated with sustained exposure, we reported in this study an inducible expression system in which the expression of gp160 is under the control of an inducible promoter. This inducible system was proven highly efficient in the control of gp160 expression in effector cells, with no expression of gp160 during maintenance and a high level of gp160 expression upon induction (data not shown). There are several advantages of inducible expression over transient transfection or regular stable expression: 1) the inducible expression system is a stable expression system, except it possesses an inducible feature; no repeated transfections are required, and thus it is highly suitable for high-throughput assays. 2) Generally inducible expression using the best stable cell clones can provide higher expression than conventional transient transfections.
3) The inducible expression system can provide highly consistent expression of the foreign gene if induced in the same way each time, although it is relatively difficult to achieve consistent expression by using transient transfection means, especially at the HTS scale. Consistent expression of gp160 is crucial for obtaining consistent fusion kinetics in the CCF system in order to produce reliable IC 50 data. 4) The expression of the gene of interest can be turned on or off simply by culturing the cells in the medium, including or excluding the inducing agent, thus avoiding any potential toxicity caused by expressed foreign proteins. 5) Because the stable inducible cell line is maintained without expression of the potentially cytotoxic foreign protein, the cell line can be highly stable. The effector cell lines described in this article that use an inducible system proved to be highly stable and produced consistent fusion signals even after 100 passages. The choice of the parental cells for the effector cells is also important because not all cell types can correctly and efficiently cleave the gp160 precursor into surface protein gp120 and transmembrane protein gp41 and present these molecules on the cell membrane. HeLa is one of the human cell lines that has been shown to be capable of efficiently processing and presenting HIV gp160 onto the cell surface. Therefore, HeLa-tet-on cells were chosen as the parental cells to generate effector cells in the fusion assay system reported here. Another important factor in the expression of HIV gp160 is the requirement of the presence of HIV accessory protein Rev. It is well known that mRNA for gp160 and other proteins that carry introns need Rev for transportation into the cytoplasm for protein synthesis. For this reason, the 2 rev exons near both ends of the gp160 coding region were included in the gp160 expression construct so that Rev is coexpressed with gp160 under the control of the same inducible expression system. A variety of eukaryotic inducible expression systems have been used for conditioned or controlled expression of many different proteins in vivo and in vitro, among which the tetracycline (tet)-inducible expression system is most widely used. [24] [25] [26] [27] [28] [29] [30] [31] However, few inducible systems have been used in cell-based assays, [29] [30] [31] and none has been used in the CCF assay systems. In the current study, the HeLa-tet-on inducible system was successfully used in both R5-and X4-CCF assay systems for the control of HIV gp160 and Rev expression. Inducible expression systems such as this can also be used for other cellbased assay systems, especially when the expressed proteins are harmful to the host cells or the proteins need to be expressed only when wanted. A variety of fusion-induced gene stimulation (FIGS) systems have been used in the CCF assays, of which the Tat-LTR gene activation has been most popular. The main reason for this is that many indicator cells can be directly used as the target cells, avoiding the need for generating an independent target cell line. It was reported that full-length HIV Tat was found to be able to transactivate the viral promoter within cells in a dose-dependent manner when added exogenously into the medium. 32, 33 The transduction domain or region conveying the cell-penetrating properties of the Tat protein appears to be confined to a small (9 amino acids) stretch of basic amino acids. 34 In our own studies, no LTR-driven β-gal reporter activation was observed when recombinant Tat proteins were added to the culture at as high as 50 µg/mL (data not shown). In the early 1990s, several laboratories reported that Tat can be secreted by HIV-infected or vector-transfected cells, and then it enters other cells in the coculture in an autocrine or paracrine manner. 35, 36 However, this cell-to-cell transmission phenomenon could not be reproduced by other laboratories. Because these observations were mostly reported before the identification of HIV coreceptors, one speculation is that the cell-to-cell transmission of Tat was actually mediated through cell-cell fusion. 37 Data shown in this article demonstrate that the Tat-LTR-luciferase reporter in the CCF systems produced minimal background and a high stimulation signal.
In the discovery of novel inhibitors targeting various steps of HIV entry, one of the key limiting factors is the lack of a robust high-throughput assay system. It is impractical to use antiviral assays to screen large compound libraries. Even though iodinelabeled ligand-binding assays have been used to screen compound libraries for CCR5 antagonists, such an approach may not be efficient enough to uncover allosteric inhibitors that primarily inhibit HIV entry other than natural ligand binding. 8 Because the fusion between the infected cells and the host cells shares the same basic mechanism as virus-cell fusion, the CCF assay is an ideal surrogate assay for antiviral assays and is suitable for HTS. The assay system described in this article uses stable cell lines and a highly sensitive and specific luciferase reporter system that is optimized for the 384-well format. This assay system generated highly coreceptordependent robust signals and very low background and exhibited excellent assay parameters, including Z′ factors ( Table 2) Z′ factor data were generated from a comparison of 30 data points per n value. Maximum values are defined as the total cellular luciferase activity in the absence of compound. Minimum values are defined as the total cellular luciferase activity in the presence of 5 µM SCH-C (R5-CCF assay) or AMD3100 (X4-CCF assay) compound. Data are mean ± SD of 8 individual experiments. Correlation of IC 50 s generated from R5-CCF assays and antiviral assays. The IC 50 data generated from R5-CCF assays and antiviral assays for 207 CCR5 antagonists were used for linear correlation analysis.
